Literature DB >> 8834911

Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

J Carratala1, A Fernandez-Sevilla, F Tubau, M A Dominguez, F Gudiol.   

Abstract

We studied 122 stool samples collected from 25 patients with hematologic malignancies who received prophylactic norfloxacin. Fecal samples were obtained at admission and twice weekly thereafter during prophylaxis. Fluoroquinolone-resistant Escherichia coli strains were isolated from the feces of 10 (40%) of the patients; two patients had fluoroquinolone-resistant E. coli strains prior to beginning norfloxacin treatment, and in the other eight patients, the strains appeared subsequently. One patient developed fluoroquinolone-resistant E. coli bacteremia after 10 days of norfloxacin administration.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8834911      PMCID： PMC163147     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Antimicrobial prophylaxis for infection in neutropenic patients.

Authors:  G P Bodey
Journal:  Curr Clin Top Infect Dis       Date:  1988

2.  Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.

Authors:  D J Winston; W G Ho; D A Bruckner; R P Gale; R E Champlin
Journal:  Am J Med       Date:  1990-01       Impact factor: 4.965

3.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

4.  Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.

Authors:  E J Bow; E Rayner; T J Louie
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

5.  Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.

Authors:  M Rozenberg-Arska; A W Dekker; J Verhoef
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

6.  Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies.

Authors:  C H Tancrède; A O Andremont
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

7.  A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia.

Authors:  J C Wade; S C Schimpff; M T Hargadon; C L Fortner; V M Young; P H Wiernik
Journal:  N Engl J Med       Date:  1981-04-30       Impact factor: 91.245

8.  Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients.

Authors:  M Giuliano; A Pantosti; G Gentile; M Venditti; W Arcese; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole.

Authors:  B E Murray; E R Rensimer; H L DuPont
Journal:  N Engl J Med       Date:  1982-01-21       Impact factor: 91.245

10.  Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies.

Authors:  R J Gualtieri; G R Donowitz; D L Kaiser; C E Hess; M A Sande
Journal:  Am J Med       Date:  1983-06       Impact factor: 4.965
View more
  21 in total

1.  Risk factors for fecal quinolone-resistant Escherichia coli in Mexican children.

Authors:  Mussaret B Zaidi; Emma Zamora; Pilar Diaz; Linda Tollefson; Paula J Fedorka-Cray; Marcia L Headrick
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract.

Authors:  Ebbing Lautenbach; Anthony D Harris; Eli N Perencevich; Irving Nachamkin; Pam Tolomeo; Joshua P Metlay
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  A near-fatal case of sepsis with an antibiotic-resistant organism complicating a routine transrectal prostate biopsy in a health care worker.

Authors:  Bryce Weber; John Saliken; Taj Jadavji; Robin R Gray; Ron Moore
Journal:  Can Urol Assoc J       Date:  2008-10       Impact factor: 1.862

4.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

5.  Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer.

Authors:  L Calatayud; M Arnan; J Liñares; M A Dominguez; C Gudiol; J Carratalà; M Batlle; J M Ribera; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

6.  Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.

Authors:  Bruno Fantin; Xavier Duval; Laurent Massias; Loubna Alavoine; Françoise Chau; Sylvie Retout; Antoine Andremont; France Mentré
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

7.  Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.

Authors:  M Oethinger; A S Jellen-Ritter; S Conrad; R Marre; W V Kern
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

8.  Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.

Authors:  M Arnan; C Gudiol; L Calatayud; J Liñares; M Á Dominguez; M Batlle; J M Ribera; J Carratalà; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-30       Impact factor: 3.267

Review 9.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

10.  Efficient recovery of fluoroquinolone-susceptible and fluoroquinolone-resistant Escherichia coli strains from frozen samples.

Authors:  Ebbing Lautenbach; Evelyn Santana; Abby Lee; Pam Tolomeo; Nicole Black; Andrew Babson; Eli N Perencevich; Anthony D Harris; Catherine A Smith; Joel Maslow
Journal:  Infect Control Hosp Epidemiol       Date:  2008-04       Impact factor: 3.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.